Wave Life Sciences (0VS) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0VS Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Wave

Life Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0VS Stock 12 Month Forecast

Average Price Target

€18.13

▲(271.51% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is €18.13 with a high forecast of €37.60 and a low forecast of €8.95. The average price target represents a 271.51% change from the last price of €4.88.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","11":"€11","20":"€20","29":"€29","38":"€38"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37.60266888,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€37.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.129858210000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.9530164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,11,20,29,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,6.03097452923077,8.66194905846154,11.292923587692309,13.923898116923079,16.554872646153846,19.185847175384616,21.816821704615386,24.447796233846155,27.078770763076925,29.709745292307694,32.340719821538464,34.97169435076923,{"y":37.60266888,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,4.533066016153846,5.666132032307692,6.799198048461538,7.932264064615385,9.06533008076923,10.198396096923076,11.331462113076924,12.46452812923077,13.597594145384615,14.730660161538461,15.863726177692309,16.996792193846154,{"y":18.129858210000002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.8271551076923074,4.254310215384615,4.681465323076923,5.10862043076923,5.535775538461538,5.962930646153845,6.390085753846153,6.81724086153846,7.244395969230768,7.671551076923075,8.098706184615382,8.525861292307692,{"y":8.9530164,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.035,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€37.60

Average Price Target€18.13

Lowest Price Target€8.95

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Madison Elsaadi

B. Riley Securities

€19.7

Buy

303.62%

Upside

Reiterated

10/12/26

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Axsome Therapeutics (AXSM)

Whitney Ijem

Canaccord Genuity

€37.6

Buy

670.55%

Upside

Reiterated

10/05/26

Wave Life Sciences: FDA-Aligned AATD Registrational Path, Obesity Combination Study, and GSK Milestones Underscore Buy Rating and $42 Price Target

Andrew Fein

H.C. Wainwright

€11.64

Buy

138.50%

Upside

Reiterated

10/02/26

Analysts Are Bullish on Top Healthcare Stocks: Johnson & Johnson (JNJ), Wave Life Sciences (WVE)

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

10/02/26

Analysts Offer Insights on Healthcare Companies: Cigna (NYSE: CI), Wave Life Sciences (NASDAQ: WVE) and Regeneron (NASDAQ: REGN)

Alec Stranahan

Bank of America Securities

€15.22

Buy

211.89%

Upside

Reiterated

10/01/26

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Liquidia Technologies (NASDAQ: LQDA) and Abbott Laboratories (NYSE: ABT)

Rick Bienkowski

Ladenburg Thalmann & Co.

€8.95

Buy

83.46%

Upside

Initiated

10/01/26

Wave Life Sciences initiated with a Buy at LadenburgWave Life Sciences initiated with a Buy at Ladenburg

Yun Zhong

Wedbush

€10.74

Buy

120.16%

Upside

Reiterated

09/30/26

Analysts Offer Insights on Healthcare Companies: Q32 Bio (NASDAQ: QTTB) and Wave Life Sciences (NASDAQ: WVE)

Tessa Romero

J.P. Morgan

―

Hold

―

Downgraded

09/23/26

Wave Life Sciences resumed with a Neutral at JPMorganWave Life Sciences resumed with a Neutral at JPMorgan

Benjamin Burnett

Wells Fargo

€12.53

Buy

156.85%

Upside

Reiterated

09/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Catherine Novack

JonesTrading

€26.86

Buy

450.39%

Upside

Reiterated

08/07/26

Salim Syed

Mizuho Securities

€24.17→€20.59

Buy

321.97%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Acurx Pharmaceuticals (NASDAQ: ACXP)

Mara Goldstein

Clear Street

€32.23→€23.28

Buy

377.00%

Upside

Reiterated

08/03/26

Wave Life Sciences price target lowered to $26 from $36 at Clear StreetWave Life Sciences price target lowered to $26 from $36 at Clear Street

Samantha Semenkow

Citi

€21.49→€17.01

Buy

248.58%

Upside

Reiterated

07/31/26

Wave Life Sciences price target lowered to $19 from $24 at CitiWave Life Sciences price target lowered to $19 from $24 at Citi

Luca Issi

RBC Capital

€13.43

Buy

175.20%

Upside

Reiterated

07/30/26

Wave Life Sciences (WVE) Receives a Buy from RBC Capital

Steven Seedhouse

Cantor Fitzgerald

€11.64

Buy

138.50%

Upside

Reiterated

05/18/26

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Gossamer Bio (NASDAQ: GOSS) and Cullinan Management (NASDAQ: CGEM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Madison Elsaadi

B. Riley Securities

€19.7

Buy

303.62%

Upside

Reiterated

10/12/26

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Axsome Therapeutics (AXSM)

Whitney Ijem

Canaccord Genuity

€37.6

Buy

670.55%

Upside

Reiterated

10/05/26

Wave Life Sciences: FDA-Aligned AATD Registrational Path, Obesity Combination Study, and GSK Milestones Underscore Buy Rating and $42 Price Target

Andrew Fein

H.C. Wainwright

€11.64

Buy

138.50%

Upside

Reiterated

10/02/26

Analysts Are Bullish on Top Healthcare Stocks: Johnson & Johnson (JNJ), Wave Life Sciences (WVE)

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

10/02/26

Analysts Offer Insights on Healthcare Companies: Cigna (NYSE: CI), Wave Life Sciences (NASDAQ: WVE) and Regeneron (NASDAQ: REGN)

Alec Stranahan

Bank of America Securities

€15.22

Buy

211.89%

Upside

Reiterated

10/01/26

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Liquidia Technologies (NASDAQ: LQDA) and Abbott Laboratories (NYSE: ABT)

Rick Bienkowski

Ladenburg Thalmann & Co.

€8.95

Buy

83.46%

Upside

Initiated

10/01/26

Wave Life Sciences initiated with a Buy at LadenburgWave Life Sciences initiated with a Buy at Ladenburg

Yun Zhong

Wedbush

€10.74

Buy

120.16%

Upside

Reiterated

09/30/26

Analysts Offer Insights on Healthcare Companies: Q32 Bio (NASDAQ: QTTB) and Wave Life Sciences (NASDAQ: WVE)

Tessa Romero

J.P. Morgan

―

Hold

―

Downgraded

09/23/26

Wave Life Sciences resumed with a Neutral at JPMorganWave Life Sciences resumed with a Neutral at JPMorgan

Benjamin Burnett

Wells Fargo

€12.53

Buy

156.85%

Upside

Reiterated

09/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Catherine Novack

JonesTrading

€26.86

Buy

450.39%

Upside

Reiterated

08/07/26

Salim Syed

Mizuho Securities

€24.17→€20.59

Buy

321.97%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE) and Acurx Pharmaceuticals (NASDAQ: ACXP)

Mara Goldstein

Clear Street

€32.23→€23.28

Buy

377.00%

Upside

Reiterated

08/03/26

Wave Life Sciences price target lowered to $26 from $36 at Clear StreetWave Life Sciences price target lowered to $26 from $36 at Clear Street

Samantha Semenkow

Citi

€21.49→€17.01

Buy

248.58%

Upside

Reiterated

07/31/26

Wave Life Sciences price target lowered to $19 from $24 at CitiWave Life Sciences price target lowered to $19 from $24 at Citi

Luca Issi

RBC Capital

€13.43

Buy

175.20%

Upside

Reiterated

07/30/26

Wave Life Sciences (WVE) Receives a Buy from RBC Capital

Steven Seedhouse

Cantor Fitzgerald

€11.64

Buy

138.50%

Upside

Reiterated

05/18/26

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (NASDAQ: WVE), Gossamer Bio (NASDAQ: GOSS) and Cullinan Management (NASDAQ: CGEM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

MDWDMediwound

OVIDOvid Therapeutics

IMUXImmunic

ASNDAscendis Pharma

AORTArtivion

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wave Life Sciences

3 Months

Joseph SchwartzLeerink Partners

Success Rate

9/20 ratings generated profit

Average Return

+14.24%

Copying Joseph Schwartz's trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of +14.24% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

12/20 ratings generated profit

Average Return

+18.53%

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +18.53% per trade.

2 Years

Salim SyedMizuho Securities

Success Rate

20/44 ratings generated profit

Average Return

+18.82%

Copying Salim Syed's trades and holding each position for 2 Years would result in 45.45% of your transactions generating a profit, with an average return of +18.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0VS Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0VS has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0VS average Analyst price target in the past 3 months is 18.13.

Each month's total comprises the sum of three months' worth of ratings.

0VS Financial Forecast

0VS Earnings Forecast

Next quarter’s earnings estimate for 0VS is -€0.30 with a range of -€0.34 to -€0.25. The previous quarter’s EPS was -€0.30. 0VS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0VS has Performed in-line its overall industry.

0VS Sales Forecast

Next quarter’s sales forecast for 0VS is €4.13M with a range of €0.00 to €17.91M. The previous quarter’s sales results were €2.03M. 0VS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0VS has Performed in-line its overall industry.

0VS Stock Forecast FAQ

What is DE:0VS’s average 12-month price target, according to analysts?

Based on analyst ratings, Wave Life Sciences’s 12-month average price target is 18.13.

What is DE:0VS’s upside potential, based on the analysts’ average price target?

Wave Life Sciences has 271.51% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Wave Life Sciences a Buy, Sell or Hold?

Wave Life Sciences has a consensus rating of Strong Buy, which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is Wave Life Sciences’s share price target?

The average share price target for Wave Life Sciences is 18.13. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €37.60 ,and the lowest forecast is €8.95. The average share price target represents 271.51% Increase from the current price of €4.88.

What do analysts say about Wave Life Sciences?

Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Wave Life Sciences?

To buy shares of DE:0VS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Wave Life Sciences (0VS) Stock Forecast & Price Target

0VS Analyst Ratings

0VS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wave Life Sciences

0VS Analyst Recommendation Trends

0VS Financial Forecast

0VS Earnings Forecast

0VS Sales Forecast

0VS Stock Forecast FAQ

Detailed List of Analyst Forecasts